CONFIRM试验方案:前列腺特异性膜抗原正电子发射断层扫描/计算机断层扫描在前列腺癌主动监测中的效用
CONFIRM试验是一项在澳大利亚维多利亚州开展的前瞻性、多中心、检验前后对照的队列研究,纳入新诊断低危前列腺癌但具有高危特征、被认为适合主动监测并接受确认性活检的男性。主要目的是确定PSMA PET/CT在风险分层中的附加价值,即能否识别出实际高危、若继续当前治疗路径可能预后不良的男性。次要目的包括评估PSMA PET/CT对重复多参数MRI的附加价值、探索在PSMA PET/CT阴性且重复mpMRI阴性(PI-RADS评分<3)的男性中能否避免确认性活检,以及开发列线图预测主动监测失败的可能性。
要点
- CONFIRM试验为前瞻性多中心队列研究,评估PSMA PET/CT在新诊断低危但具高危特征前列腺癌患者主动监测风险分层中的附加价值。
- 主要结局为基于病理升级和多学科团队推荐判定不适合继续主动监测的男性比例,原因归因于PSMA PET/CT和PSMA靶向确认性活检。
- 将计算PSMA PET/CT单独及联合重复mpMRI的阳性预测值、阴性预测值、敏感性和特异性。
核心结论
- 该试验将提供稳健的前瞻性数据,以确定PSMA PET/CT联合标准治疗(前列腺活检±重复mpMRI)能否提高因低级别前列腺癌伴高危特征而接受确认性活检的男性的诊断确定性。
研究设计与样本
- CONFIRM试验是一项在澳大利亚维多利亚州开展的前瞻性、多中心、检验前后对照的队列研究。
- 研究对象为新诊断低危前列腺癌但具有高危特征、被认为适合主动监测并接受确认性活检的男性。
主要发现
- 该试验将测量基于病理升级和多学科团队推荐、因PSMA PET/CT扫描和PSMA靶向确认性活检而被判定不适合继续主动监测的男性比例。
- 将计算PSMA PET/CT单独及联合重复mpMRI的阳性预测值、阴性预测值、敏感性和特异性。
关键数值与推荐
- 重复mpMRI阴性定义为前列腺影像报告和数据系统(PI-RADS)评分<3。
- 将抽取血样在确认性活检时进行前列腺健康指数检测。
- 部分血样将储存于生物样本库最多5年,若基于CONFIRM试验结果提示有必要对该队列男性进行分子生物标志物和遗传学检测的随访研究。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Primary objectives: To determine the additive value of prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in the risk stratification of men with newly diagnosed prostate cancer (PCa) who would have otherwise been deemed suitable for active surveillance (AS). Specifically, we aim to determine if PSMA PET/CT can detect a cohort of men on AS that are in fact high risk and likely to experience unfavourable outcomes should they remain on their current treatment pathway. SECONDARY OBJECTIVES: to determine the additive value of PSMA PET/CT to repeat multiparametric magnetic resonance imaging (mpMRI) of the prostate and explore whether a confirmatory biopsy may be avoided in men with a negative PSMA PET/CT and a negative repeat mpMRI of the prostate (Prostate Imaging-Reporting and Data System score of <3). Furthermore, to develop a nomogram combining clinical, imaging and biomarker data to predict the likelihood of failure on AS in men with high-risk features. Also, a blood sample will be taken to perform a Prostate Health Index test at the time of confirmatory biopsy. Furthermore, a portion of this blood will be stored at a biobank for up to 5 years if a follow-up study on molecular biomarkers and genetic assays in this cohort of men is indicated, based on the results from the CONFIRM trial. PATIENTS AND METHODS: The CONFIRM trial is a prospective, multicentre, pre-test/post-test, cohort study across Victoria, Australia, involving men with newly diagnosed low-risk PCa with high-risk features, considered suitable for AS and undergoing confirmatory biopsy. The trial's goal is to provide high-quality evidence to establish whether PSMA PET/CT has a role in risk-stratifying men deemed suitable for AS despite having high-risk feature(s). RESULTS: The CONFIRM trial will measure the proportion of men deemed unsuitable for ongoing AS based on pathological upgrading and multidisciplinary team recommendation due to PSMA PET/CT scan and PSMA-targeted confirmatory biopsy. Additionally, the positive and negative predictive values, sensitivity, and specificity of PSMA PET/CT will be calculated in isolation and combined with repeat mpMRI of the prostate. CONCLUSIONS: This trial will provide robust prospective data to determine if PSMA-PET/CT and standard of care (prostate biopsy ± repeat mpMRI) can improve diagnostic certainty in men undergoing confirmatory biopsy for low-grade PCa with high-risk features.
引用
- Bagguley D, Harewood L, McKenzie D, et al. The CONFIRM trial protocol: the utility of prostate-specific membrane antigen positron emission tomography/computed tomography in active surveillance for prostate cancer. BJU Int. 2023. PMID: 37904302. doi:10.1111/bju.16214
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。